Skip to Content

The Medicines Company (NASDAQ: MDCO)

Merger

  • Date:
  • 11/25/2019
  • Company Name:
  • The Medicines Company
  • Stock Symbol:
  • MDCO
  • Company Name - Buyer:
  • Novartis AG
  • Merger Announcement Date:
  • 11/24/2019

Case Finder

Locate any case using the tools below.

NEW YORK, November 25, 2019 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, has launched an investigation into whether the board members of The Medicines Company (NASDAQ: MDCO) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to Novartis AG.

On November 24, 2019, The Medicines Company announced that it had signed an agreement to be acquired by Novartis AG for $85 per share in cash, or a total of approximately $9.7 billion. The deal is scheduled to close in the first quarter of 2020. Bragar Eagel & Squire is concerned that The Medicines Company’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for The Medicines Company shareholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in The Medicines Company. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: